Cargando…
Pembrolizumab as second-line therapy in non-small cell lung cancer in northern Norway: budget impact and expected gain—a model-based analysis
BACKGROUND: Pembrolizumab is a new drug approved in several countries for second-line therapy in non-small cell lung cancer (NSCLC) being programmed cell death ligand (PD-L1) positive. This drug has a high cost, and the cost-effectiveness ratio has been debated. PATIENTS AND METHODS: The budget impa...
Autores principales: | Norum, Jan, Antonsen, Margareth Aarag, Tollåli, Terje, Al-Shibli, Khalid, Andersen, Gry, Svanqvist, Kristin Helene, Helbekkmo, Nina |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5703383/ https://www.ncbi.nlm.nih.gov/pubmed/29209527 http://dx.doi.org/10.1136/esmoopen-2017-000222 |
Ejemplares similares
-
PET-CT in the sub-arctic region of Norway 2010–2013. At the edge of what is possible?
por: Norum, Jan, et al.
Publicado: (2015) -
The economic burden of TNFα inhibitors and other biologic treatments in Norway
por: Norum, Jan, et al.
Publicado: (2011) -
Nontargeted Effect after Radiotherapy in a Patient with Non-Small Cell Lung Cancer and Bullous Pemphigoid
por: Nieder, Carsten, et al.
Publicado: (2015) -
Socioeconomic characteristics and health outcomes in Sami speaking municipalities and a control group in northern Norway
por: Norum, Jan, et al.
Publicado: (2012) -
Wrist malpractice claims in Northern Norway 2005–2014. Lessons to be learned
por: Norum, Jan, et al.
Publicado: (2018)